Skip to content
Screener

Roivant Sciences ROIV Pre-Tax Income

Discontinued — last reported Q1 '26

Pre-Tax Income at other companies

Amgen logo
AmgenAMGN
$2.77B+76.5%
Moderna logo
ModernaMRNA
-$767M+6.2%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$150.7M-42.3%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.09B+130%
AbbVie logo
AbbVieABBV
$4.28B+175%
CNT
Canton Strategic HoldingsCNTN
-$51.56M-1,929%

Segments

By geography

See full
United States-$354.51M-103%
Bermuda$62.37M+177%
Switzerland$21.71M+105%

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$25.37B+219%
Enterprise value$25.4B+219%
P/S3,368×+3,026×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q2 2026
Accession
0001635088-26-000090
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025
Change in fair value of liability instruments2,329
Interest income(36,922)(48,322)
Other expense, net2,13011,208
Loss before income taxes(294,564)(269,262)
Income tax (benefit) expense(3,958)4,649
Net loss(290,606)(273,911)
Net loss attributable to noncontrolling interests(100,769)(50,556)
Net loss attributable to Roivant Sciences Ltd.$(189,837)$(223,355)

Item 1. Financial Statements (Unaudited).

FAQ

What is Roivant Sciences's pre-tax income?
Roivant Sciences (ROIV) reported pre-tax income of -$294.56M in Q2 2026.
How has Roivant Sciences's pre-tax income changed year-over-year?
Roivant Sciences's pre-tax income decreased by 9.4% year-over-year, from -$269.26M to -$294.56M.
What is the long-term trend for Roivant Sciences's pre-tax income?
Over 2 years (2021 to 2024), Roivant Sciences's pre-tax income has grown at a -14.1% compound annual growth rate (CAGR), from -$923.75M to -$681.59M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Roivant Sciences's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude